STEP HFpEF: once-weekly semaglutide in people with HFpEF and obesity - report from ESC2023

from Medical Digest & Congress Report · host Medical Congress News

Professor Mikhail Kosiborod provides a summary of the STEP HFpEF trial, in which semaglutide improves heart failure-related symptoms and physical function and results in greater weight loss compared with placebo in patients with heart failure with preserved ejection fraction and obesity, according to late breaking research presented at ESC Congress 2023. Video: https://medicaldigest.org/scientific-contents/interview:step-hfpef-once-weekly-semaglutide-people-hfpef-and-obesity

Episode metadata supplied by the publisher feed · Published Sep 11, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

STEP HFpEF: once-weekly semaglutide in people with HFpEF and obesity - report from ESC2023

0:00 3:20

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 3 minutes long.

When was this Medical Digest & Congress Report episode published?

This episode was published on September 11, 2023.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!